Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Oligomers and oligomer conjugates
US2024035032A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024035032-A1 |
| Application number | US-202318114626-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 27, 2023 |
| Priority date | May 15, 2014 |
| Publication date | Feb 1, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
First claim
Opening claim text (preview).
1 . An oligomer conjugate suitable for use in the treatment of a viral disorder, wherein said oligomer conjugate comprises: a) at least one first oligomer region capable of modulating a target sequence of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component; wherein said first oligomer region is 10-20 nucleotides in length; wherein said carrier component is a asialoglycoprotein receptor (ASGP-R) targeting moiety or a cholesterol conjugate moiety; and wherein said target sequence comprises at least part of a gene or a mRNA encoding HBx (SEQ ID NO: 1) or HBsAg (SEQ ID NO: 2) or a naturally-occurring variant thereof. 2 .- 21 . (canceled)
Assignees
Inventors
Classifications
- C12N15/1131Primary
against viruses · CPC title
Sugars, nucleosides, nucleotides or nucleic acids · CPC title
the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid · CPC title
- C12N15/1133Primary
against herpetoviridae, e.g. HSV · CPC title
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024035032A1 cover?
- The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1131. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).